Selenium and Restless Leg Syndrome

The effect of selenium administration on Restless leg syndrome treatment

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103015943N1

Enrollment

Registered

2011-05-20

Start date

2010-06-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Restless Leg Syndrome. Other specified extrapyramidal and movement disorders

Interventions

Intervention 1: First month: placebo

one capsule daily. Intervention 2: Second month: 50 microgram of selenium one capsule daily. Intervention 3: Third month: 200 microgram of selenium, one capsule daily.

Placebo

Treatment - Drugs

First month: placebo

one capsule daily

Second month: 50 microgram of selenium one capsule daily

Third month: 200 microgram of selenium, one capsule daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Idiopathic form of disease Exclusion criteria: Secondary form of disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
RLS Index. Timepoint: Monthly. Method of measurement: based on IRLSG (International RLS Study Group).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Mellat Ardekani

Shahid Sadoughi Hospital, Yazd University of Medical Sciences

ALI_MELLAT@SSU.AC.IR , ALI_MELLAT@YAHOO.COM+98 35 1822 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026